Why it matters: The financing is the second largest private biotech round of 2026 in Europe folowing Isomorphic’s $2.1 billion Series B in May, and brings OMass’ total funding to approximately $475 million (about €423 million). It gives the University of Oxford spinout the resources to advance two internally discovered drug candidates through clinical development while building a larger biotechnology company.
Who’s investing: The oversubscribed round was co-led by Bain Capital Life Sciences, Forbion (which just raised a €2.3 billion fund) and Novo Holdings, with new investors Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences joining the syndicate. Existing investors also participated, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank and the University of Oxford.
Zoom in: Most of the proceeds will support OMS1620, an oral antagonist of the melanocortin-2 (MC2) receptor, through Phase 2 development in congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome.
- CAH is a rare genetic condition in which the adrenal glands cannot produce sufficient cortisol. Patients typically require lifelong glucocorticoid treatment, often at doses exceeding normal physiological levels, to control excess androgen production. Prolonged exposure to high steroid doses can cause serious complications.
How it works: OMass aims to address this problem by blocking the action of adrenocorticotropic hormone (ACTH) at the adrenal gland, reducing androgen production while allowing patients to receive lower glucocorticoid doses.
- The company designed OMS1620 to remain bound to its receptor for longer, potentially maintaining activity even when ACTH levels rise. Preclinical data suggest this could provide an advantage over competing treatments, although the claim has yet to be established clinically. The candidate is currently in the single-ascending-dose stage of Phase 1 testing.
The big picture: OMass is entering a field with increasingly established competitors.
- Vertex Pharmaceuticals acquired Crinetics Pharmaceuticals for approximately $10 billion in September, gaining atumelnant, another oral MC2 receptor antagonist. Atumelnant is already in Phase 3 development for CAH and Phase 2 for Cushing’s syndrome. Phase 2 results showed sustained reductions in androgen levels while enabling lower glucocorticoid doses.
- Neurocrine Biosciences has already brought Crenessity (crinecerfont) to market for CAH. Unlike the Vertex and OMass candidates, Crenessity blocks CRF1 receptors upstream of ACTH production. The company has reported two-year clinical data showing sustained hormone control and reduced glucocorticoid exposure in pediatric patients.
Beyond endocrinology: The financing will also fund initial clinical development of an SLC15A4 inhibitor targeting lupus and other autoimmune diseases characterized by excessive interferon signaling and pathogenic B-cell activation.
- SLC15A4 has attracted growing interest as a potential target for orally administered immunotherapies. OMass believes its approach could intervene upstream in the inflammatory pathway, offering a small-molecule alternative to more complex treatments.
Backstory: Founded in 2016 around research from University of Oxford professor Carol Robinson, OMass uses its OdyssION platform, combining native mass spectrometry, biochemistry and medicinal chemistry, to study drug targets in their natural protein environments.
What’s next: The immediate test will be whether OMS1620’s proposed pharmacological advantages translate into meaningful clinical benefits. With Vertex already running late-stage trials in the same indication, OMass will need compelling clinical data to establish a competitive position.
Source: european-biotechnology.com
